Physician profile
Thomas B Pinto
NPI 1104827872
$2,559.68
in general payments reported to CMS, 2019-2025
24 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,299 · 2020: $950 · 2021: $296 · 2022: $15.00.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $471.43 | 2019-2021 | |
| Amgen INC. | $414.34 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $331.94 | 2019-2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $226.35 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $194.47 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $152.19 | 2019 | |
| Amarin Pharma, INC. | $95.35 | 2020-2021 | |
| Pfizer INC. | $90.04 | 2019-2021 | |
| Boston Scientific Corporation | $89.12 | 2019-2021 | |
| Abbott Laboratories | $71.05 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $64.09 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $43.67 | 2019-2020 | |
| Alnylam Pharmaceuticals INC. | $43.09 | 2019-2021 | |
| Daiichi Sankyo INC. | $40.70 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $37.94 | 2019-2020 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Atricure, INC. | $36.78 | 2019 | |
| Lundbeck LLC | $30.43 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $29.18 | 2020 | |
| Actelion Pharmaceuticals US, INC. | $18.62 | 2019-2020 | |
| Vifor Pharma, INC. | $18.51 | 2021 | |
| Esperion Therapeutics, INC. | $18.33 | 2020 | |
| Otsuka America Pharmaceutical, INC. | $15.84 | 2019 | |
| Gilead Sciences, INC. | $13.68 | 2019 | |
| Lilly USA, LLC | $12.54 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Pinto listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.